Doctor profile · Federal record
Dr. Nancy Moua, FNP
Family Medicine Physician (CMS: Nurse Practitioner) · Milpitas, CA
- NPI 1144744616
- Accepts Medicare
- 11 yrs in practice
- Female
- Solo practice
- No sanctions
Practice & contact
- Primary practice
-
670 N McCarthy Blvd Ste 220
Milpitas, CA 950355119
(408) 582-4113
Credentials & registration
- NPI registered
- July 2017 — 9 yrs on file
- Profile last updated
- July 21, 2022
- Year of graduation
- 2015 — 11 yrs since
- Specialty taxonomy
- 207Q00000X — NUCC code
- State license (1)
- California #95003432
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1144744616. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
21,222
Distinct HCPCS
5
Medicare allowed
$492,832
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J1306 |
Injection, inclisiran, 1 mg | 9,940 | 25 | $12 | |
J2357 |
Injection, omalizumab, 5 mg | 7,740 | 14 | $38 | |
J0897 |
Injection, denosumab, 1 mg | 3,060 | 43 | $23 | |
96372 |
Injection of drug or substance under skin or into muscle | 458 | 111 | $15 | |
96413 |
Administration of chemotherapy into vein, 1 hour or less | 24 | 12 | $151 |
In context: peer comparison
Among 1 peers in this city , average services per provider: 4,244. This provider delivers 5.0× the peer median.Frequently asked questions
What is Dr. Nancy Moua's medical specialty?
Dr. Nancy Moua practices Family Medicine Physician in Milpitas, CA.
Where does Dr. Nancy Moua practice?
Dr. Nancy Moua practices at 670 N McCarthy Blvd Ste 220, Milpitas, CA 950355119. Office phone: 4085824113.
What is Dr. Nancy Moua's NPI?
Dr. Nancy Moua's National Provider Identifier (NPI) is 1144744616, issued by NPPES.
Does Dr. Nancy Moua accept Medicare assignment?
Yes. Dr. Nancy Moua accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Nancy Moua commonly perform?
Top Medicare-reported procedures in 2023: Injection, inclisiran, 1 mg (HCPCS J1306); Injection, omalizumab, 5 mg (HCPCS J2357); Injection, denosumab, 1 mg (HCPCS J0897). Source: CMS Medicare Physician & Other Practitioners file.